
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of **March, 2019**

Commission File Number: **001-38480**

IMV Inc.

(Name of registrant)

130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

IMV Inc.

Date: March 7, 2019

By: /s/ Pierre Labbé
Name: Pierre Labbé
Title: Chief Financial Officer

Form 6-K Exhibit Index

**Exhibit
Number**

Document Description

[99.1](#)

[News Release dated March 7, 2019. IMV Inc. to Present at the Cowen and Company 39th Annual Health Care Conference](#)



**IMV Inc. to Present at the Cowen and Company
39th Annual Health Care Conference**

Dartmouth, March 7, 2019 – IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that [Pierre Labbé, IMV's Chief Financial Officer](#) will present at the [Cowen and Company 39th Annual Health Care Conference](#), which will be held March 11-13, 2019 in Boston, MA.

IMV's presentation details include:

- **Date:** Wednesday, March 13, 2019
- **Time:** 9:20 – 9:50 a.m. ET
- **Location:** Salon C, 4th Floor at The Marriott Copley Hotel, Boston, MA

There will be a live webcast of IMV's presentation accessible thru the IMV website at: <http://wsw.com/webcast/cowen52/imv/> and the presentation will then be archived for 90 days afterwards. A copy of the presentation will also be available in the Events & Presentations section of IMV's website: www.imv-inc.com.

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells *in vivo*, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at www.imv-inc.com.

###

Source: IMV Inc.

Investor Relations:

Marc Jasmin, IMV Senior Director, Investor Relations and Communications
O: (902) 492-1819 ext : 1042
M: (514) 617-9481 E: mjasmin@imv-inc.com

Media:

Andrea Cohen, Sam Brown Inc.
T: (917) 209-7163 E: andreacohen@sambrown.com
